Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04023071 · ClinicalTrials.gov registry record · Phase 1
FT516 in Subjects With Advanced Hematologic Malignancies
A Phase 1 study, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT04023071 is a Phase 1 study that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 72 participants.
The verdict
NCT04023071, a Phase 1 study, was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.
Interventions
- DRUG Obinutuzumab
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Rituximab
- DRUG FT516
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-10-04 |
| Est. Completion | 2023-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04023071
The ClinicalTrials.gov registry entry for NCT04023071 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT04023071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04023071 about?
NCT04023071 is a clinical study titled "FT516 in Subjects With Advanced Hematologic Malignancies". This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.
What is the current status of trial NCT04023071?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2019-10-04. Estimated completion is 2023-10-23.
What interventions are being tested in trial NCT04023071?
The interventions under investigation include: Obinutuzumab (DRUG), Cyclophosphamide (DRUG), Fludarabine (DRUG), Rituximab (DRUG), FT516 (DRUG).
Who is sponsoring clinical trial NCT04023071?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.